Literature DB >> 25483686

Consumer reporting of adverse events following immunization.

Hazel J Clothier1, Gowri Selvaraj, Mee Lee Easton, Georgina Lewis, Nigel W Crawford, Jim P Buttery.   

Abstract

Surveillance of adverse events following immunisation (AEFI) is an essential component of vaccine safety monitoring. The most commonly utilized passive surveillance systems rely predominantly on reporting by health care providers (HCP). We reviewed adverse event reports received in Victoria, Australia since surveillance commencement in July 2007, to June 2013 (6 years) to ascertain the contribution of consumer (vaccinee or their parent/guardian) reporting to vaccine safety monitoring and to inform future surveillance system development directions. Categorical data included were: reporter type; serious and non-serious AEFI category; and, vaccinee age group. Chi-square test and 2-sample test of proportions were used to compare categories; trend changes were assessed using linear regression. Consumer reporting increased over the 6 years, reaching 21% of reports received in 2013 (P<0.001), most commonly for children aged less than 7 years. Consumer reports were 5% more likely to describe serious AEFI than HCP (P=0.018) and 10% more likely to result in specialist clinic attendance (P<0.001). Although online reporting increased to 32% of all report since its introduction in 2010, 85% of consumers continued to report by phone. Consumer reporting of AEFI is a valuable component of vaccine safety surveillance in addition to HCP reporting. Changes are required to AEFI reporting systems to implement efficient consumer AEFI reporting, but may be justified for their potential impact on signal detection sensitivity.

Entities:  

Keywords:  AEFI, Adverse event following immunization; HCP, Health care provider; adverse event; consumer; immunisation; safety; surveillance; vaccine

Mesh:

Year:  2014        PMID: 25483686      PMCID: PMC4514059          DOI: 10.4161/hv.34369

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  18 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Parental concerns and medical-seeking behavior after immunization.

Authors:  Deborah A Gust; Scott Campbell; Allison Kennedy; Irene Shui; Lawrence Barker; Benjamin Schwartz
Journal:  Am J Prev Med       Date:  2006-06-06       Impact factor: 5.043

3.  Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies.

Authors:  Jan Bonhoeffer; Adwoa Bentsi-Enchill; Robert T Chen; Margaret C Fisher; Michael S Gold; Katharina Hartman; Ulrich Heininger; Bernard Hoet; Thomas Jefferson; Najwa Khuri-Bulos; Katrin S Kohl; S Michael Marcy; David Nalin; Robert Pless; Hernan Sanabria-Rojas; Karen Sleeman; Robert Wise
Journal:  Vaccine       Date:  2008-12-03       Impact factor: 3.641

Review 4.  Active surveillance for adverse events following immunization.

Authors:  Nigel W Crawford; Hazel Clothier; Kate Hodgson; Gowri Selvaraj; Mee Lee Easton; Jim P Buttery
Journal:  Expert Rev Vaccines       Date:  2013-12-18       Impact factor: 5.217

5.  Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria.

Authors:  Hazel J Clothier; Nigel W Crawford; Ann Kempe; Jim P Buttery
Journal:  Commun Dis Intell Q Rep       Date:  2011-12

6.  Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.

Authors:  Adriana Parrella; Michael Gold; Annette Braunack-Mayer; Peter Baghurst; Helen Marshall
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

7.  Parental perspectives of vaccine safety and experience of adverse events following immunisation.

Authors:  Adriana Parrella; Michael Gold; Helen Marshall; Annette Braunack-Mayer; Peter Baghurst
Journal:  Vaccine       Date:  2013-02-17       Impact factor: 3.641

8.  How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.

Authors:  Lorna Hazell; Victoria Cornelius; Philip Hannaford; Saad Shakir; Anthony J Avery
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 9.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study.

Authors:  Adriana Parrella; Annette Braunack-Mayer; Michael Gold; Helen Marshall; Peter Baghurst
Journal:  BMC Health Serv Res       Date:  2013-08-15       Impact factor: 2.655

View more
  16 in total

1.  An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.

Authors:  Kumanan Wilson; Katherine M Atkinson; Jacqueline Westeinde; Cameron Bell; Kim Marty; Dean Fergusson; Shelley L Deeks; Natasha Crowcroft; Julie A Bettinger
Journal:  Hum Vaccin Immunother       Date:  2016-02-23       Impact factor: 3.452

2.  Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.

Authors:  Hazel J Clothier; Nigel W Crawford; Melissa Russell; Heath Kelly; Jim P Buttery
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

3.  Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.

Authors:  E S Littlejohn; H J Clothier; K P Perrett; M Danchin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.

Authors:  Kinan Mokbel; Rob Daniels; Michael N Weedon; Leigh Jackson
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

5.  Adverse events following HPV immunization in Australia: Establishment of a clinical network.

Authors:  Nigel W Crawford; Kate Hodgson; Mike Gold; Jim Buttery; Nicholas Wood
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

6.  The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis.

Authors:  Leàn Rolfes; Florence van Hunsel; Laura van der Linden; Katja Taxis; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

7.  Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.

Authors:  Hazel J Clothier; Nigel Crawford; Melissa A Russell; Jim P Buttery
Journal:  Euro Surveill       Date:  2017-05-18

8.  Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database.

Authors:  Leàn Rolfes; Florence van Hunsel; Ola Caster; Henric Taavola; Katja Taxis; Eugène van Puijenbroek
Journal:  Br J Clin Pharmacol       Date:  2018-04-19       Impact factor: 4.335

9.  2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.

Authors:  Julie A Bettinger; Gaston De Serres; Louis Valiquette; Otto G Vanderkooi; James D Kellner; Brenda L Coleman; Karina A Top; Jennifer E Isenor; Anne E McCarthy
Journal:  Euro Surveill       Date:  2020-06

10.  Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017.

Authors:  F Moretti; L Gonella; S Gironi; A R Marra; C Santuccio; P Felicetti; F Petronzelli; P Marchione; S A Barnaba; A Poli; G Zanoni; U Moretti
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.